Cilazapril hydrochloride  (Synonyms: Ro 31-2848 hydrochloride)

Cilazapril hydrochloride is an orally active prodrug of the angiotensin-converting enzyme (ACE) inhibitor Cilazaprilat (HY-A0113). Cilazapril hydrochloride reduces plasma ACE activity. Cilazapril hydrochloride can be used in the research of hypertension (including essential and renal hypertension) and congestive heart failure^{[1][2][3][4][5]}.

Cilazapril (0.1 mg/kg; p.o.) hydrochloride evokes the same maximum degree of plasma ACE inhibition (-76%) in rats as 0.25 mg/kg Enalapril (HY-B0331)^[1].
Cilazapril (0.1-0.3 mg/kg orally) hydrochloride dose-dependently reduces plasma ACE activity and the pressor response to angiotensin in cats^[1].
Cilazapril (10 mg/kg orally twice daily for 3.5 days) hydrochloride gradually reduces blood pressure in dogs with volume-depleted renal hypertension.
Cilazapril (10 mg/kg; p.o.; 2 weeks) hydrochloride decreases blood pressure, reduces heart weight to body weight ratio, and improves postischemic myocardial function in hyperthyroid rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

453.96

C₂₂H₃₂ClN₃O₅

88824-78-6

OC([C@H]1N2N(CCC[C@@H](C2=O)N[C@H](C(OCC)=O)CCC3=CC=CC=C3)CCC1)=O.Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Waterfall JF. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor. Br J Clin Pharmacol. 1989;27 Suppl 2(Suppl 2):139S-150S.  [Content Brief]

  [2]. Bhutto IA, et al. Effects of cilazapril on the retinal vessels in spontaneously hypertensive rats: corrosion cast and scanning electron microscopic study. Life Sci. 1999;64(3):PL27-39.  [Content Brief]

  [3]. Asahi T, et al. Cilazapril prevents cardiac hypertrophy and postischemic myocardial dysfunction in hyperthyroid rats. Thyroid. 2001 Nov;11(11):1009-15.  [Content Brief]

  [4]. Szucs, T., Cilazapril. A review. Drugs, 1991. 41 Suppl 1: p. 18-24.  [Content Brief]

  [5]. Nussberger, J., et al., Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol, 1987. 9(1): p. 39-44.  [Content Brief]